Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes
New Phase 3 RECOVERY Trial to Include Approximately 250 Participants Trial to Commence First Quarter 2019 With Topline Data Expected […]